Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus

This study aimed to elucidate the pharmacokinetic/pharmacodynamic and pharmacodynamic/efficacy relationships of anifrolumab, a type I interferon receptor antibody, in patients with moderate to severe systemic lupus erythematosus. Data were pooled from the randomized, 52‐week, placebo‐controlled TULI...

Descripción completa

Detalles Bibliográficos
Autores principales: Chia, Yen Lin, Tummala, Raj, Mai, Tu H., Rouse, Tomas, Streicher, Katie, White, Wendy I., Morand, Eric F., Furie, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545691/
https://www.ncbi.nlm.nih.gov/pubmed/35352835
http://dx.doi.org/10.1002/jcph.2054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545691/
https://www.ncbi.nlm.nih.gov/pubmed/35352835
http://dx.doi.org/10.1002/jcph.2054

Ejemplares similares